What technical indicators reveal about PROK stock

Arcelia Reed

While ProKidney Corp has overperformed by 2.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PROK rose by 75.15%, with highs and lows ranging from $7.13 to $0.46, whereas the simple moving average jumped by 78.96% in the last 200 days.

On June 30, 2025, BofA Securities Downgraded ProKidney Corp (NASDAQ: PROK) to Underperform. A report published by JP Morgan on September 30, 2024, Initiated its previous ‘Neutral’ rating for PROK. Guggenheim also rated PROK shares as ‘Buy’, setting a target price of $6 on the company’s shares in an initiating report dated September 10, 2024. Morgan Stanley Initiated an Equal-Weight rating on March 07, 2024, and assigned a price target of $3. BofA Securities January 02, 2024d its ‘Buy’ rating to ‘Neutral’ for PROK, as published in its report on January 02, 2024. BTIG Research’s report from July 25, 2023 suggests a price prediction of $16 for PROK shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.

Analysis of ProKidney Corp (PROK)

One of the most important indicators of ProKidney Corp’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 11.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

For any stock, average volume can also provide valuable insight into volatility, and PROK is recording 13.28M average volume. On a monthly basis, the volatility of the stock is set at 9.34%, whereas on a weekly basis, it is put at 8.30%, with a gain of 22.31% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.40, showing growth from the present price of $2.96, which can serve as yet another indication of whether PROK is worth investing in or should be passed over.

How Do You Analyze ProKidney Corp Shares?

Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 27.57%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.46% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.